Skip to main content
KANGSTEM BIOTECH CO., LTD. logo

KANGSTEM BIOTECH CO., LTD. — Investor Relations & Filings

Ticker · 217730 ISIN · KR7217730001 KO Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2023-08-30 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 217730

About KANGSTEM BIOTECH CO., LTD.

https://kangstem.com

KANGSTEM BIOTECH CO., LTD. is a biopharmaceutical company that researches and develops advanced stem cell therapies. The company focuses on creating treatments for rare, incurable, and autoimmune diseases, with a pipeline that includes therapeutic candidates for neurological disorders. Leveraging proprietary technologies for the isolation and mass culture of mesenchymal stem cells, Kangstem Biotech also develops and commercializes stem cell culture media and related cosmetic products. The company is dedicated to addressing unmet medical needs through the development of next-generation biopharmaceuticals.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주요사항보고서(유상증자결정) 정정신고' (Report on Material Matters: Amendment to Capital Increase Decision). It details specific changes to the terms of a capital increase (rights offering), including dates for subscription, payment, and listing. This falls under the category of announcements regarding new share issues or capital changes.
2023-08-30 Korean
[기재정정]증권신고서(지분증권) (2023.10)
Share Issue/Capital Change Classification · 95% confidence The document is a 'Securities Registration Statement' (증권신고서) filed by Kangstem Biotech. It details amendments (정정신고) to a previously filed registration statement, specifically updating schedules, investment risks, and clinical trial information. In the context of Korean financial filings (DART system), a 'Securities Registration Statement' is a regulatory filing used for public offerings or capital raises. Since it is a formal regulatory document detailing the terms of a securities offering and is not a periodic report (like a 10-K or IR) or a simple announcement, it falls under the 'Regulatory Filings' category.
2023-08-30 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding the scheduling and details of an Investor Relations (IR) event (기업설명회). It provides the date, time, location, and purpose of the meeting. Since it is an announcement of an upcoming presentation rather than the presentation slides themselves, and it fits the criteria for a regulatory announcement regarding corporate activities, it is classified as a Regulatory Filing (RNS).
2023-08-29 Korean
[기재정정]증권신고서(지분증권) (2023.10)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서(지분증권) 정정신고' (Securities Registration Statement Amendment) filed by Kangstem Biotech. It details specific amendments made to a previously filed registration statement to reflect the company's 2023 semi-annual report (2023년 반기보고서). This type of filing is a regulatory document related to capital raising and public offerings, which falls under the 'Regulatory Filings' category as it is a formal amendment to a securities registration statement.
2023-08-25 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details a specific transaction (장내매수 - open market purchase) of shares by a company executive (Na Jong Cheon). This type of filing is classified as a Director's Dealing (DIRS) as it reports personal share transactions by company directors/executives.
2023-08-22 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details a transaction (a purchase of shares) by an executive (Bae Yohan) of the company Kangstem Biotech. This type of filing is a standard regulatory requirement for reporting insider trading or changes in share ownership by company directors/executives, which corresponds to the 'Director's Dealing' category.
2023-08-22 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.